

## Special Issue

# Adjuvant Therapy for Pancreatic Cancer

### Message from the Guest Editor

Pancreatic cancer is one of the deadliest cancers with a dismal prognosis. The currently employed radiological tests are ineffective for identifying micro-metastatic disease, which indicates the requirement of biomarkers for the early detection of metastatic features in PDAC patients. Furthermore, the effect of adjuvant radiation therapy leading to improved outcomes of PDAC patients is debatable, owing to the scarcity of data that can validate the techniques and dosage used for radiotherapy. This Special Issue will highlight the current treatment options in pancreatic cancer, the progress demonstrated by new strategies, future prospects for improving targeted therapies and effective neoadjuvant therapies that offer improved survival benefits to patients with this extremely complex and heterogeneous disease.

---

#### Guest Editor

Dr. Sonam Kumari

Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA

---

#### Deadline for manuscript submissions

30 September 2025



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/170037](https://mdpi.com/si/170037)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)